Robert J Commons
Overview
Explore the profile of Robert J Commons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rajasekhar M, Simpson J, Ley B, Edler P, Chu C, Abreha T, et al.
Lancet Infect Dis
. 2023 Sep;
24(2):184-195.
PMID: 37748497
Background: Primaquine radical cure is used to treat dormant liver-stage parasites and prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We undertook a systematic review and...
12.
Commons R, Rajasekhar M, Edler P, Abreha T, Awab G, Baird J, et al.
Lancet Infect Dis
. 2023 Sep;
24(2):172-183.
PMID: 37748496
Background: Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy...
13.
Yilma D, Groves E, Brito-Sousa J, Monteiro W, Chu C, Thriemer K, et al.
Am J Trop Med Hyg
. 2023 Aug;
109(4):761-769.
PMID: 37604475
Primaquine (PQ) kills Plasmodium vivax hypnozoites but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. We conducted two systematic reviews. The first used data from clinical trials...
14.
Thriemer K, Commons R
Lancet Infect Dis
. 2023 May;
23(10):1100-1102.
PMID: 37236222
No abstract available.
15.
Moyo N, Tay E, Trauer J, Burke L, Jackson J, Commons R, et al.
PLoS One
. 2023 Mar;
18(3):e0282884.
PMID: 36943855
Background: Regionality is often a significant factor in tuberculosis (TB) management and outcomes worldwide. A wide range of context-specific factors may influence these differences and change over time. We compared...
16.
Mohammed H, Sime H, Hailgiorgis H, Chernet M, Alebachew M, Solomon H, et al.
Malar J
. 2022 Dec;
21(1):401.
PMID: 36587210
Background: Declining efficacy of chloroquine for the treatment Plasmodium vivax malaria has been reported in different endemic settings in Ethiopia. This highlights the need to assess alternative options for P....
17.
Watson J, Commons R, Tarning J, Simpson J, Llanos Cuentas A, Lacerda M, et al.
Elife
. 2022 Dec;
11.
PMID: 36472067
Tafenoquine is a newly licensed antimalarial drug for the radical cure of malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual data from 1102 patients and...
18.
Mohammed H, Sime H, Hailgiorgis H, Gubae K, Haile M, Solomon H, et al.
Malar J
. 2022 Nov;
21(1):351.
PMID: 36437454
Background: Declining efficacy of chloroquine against Plasmodium vivax malaria has been documented in Ethiopia. Thus, there is a need to assess the efficacy of alternative schizontocidal anti-malarials such as dihydroartemisinin-piperaquine...
19.
Vasey C, Watson E, Commons R, Liang R, Nestel D
Br J Surg
. 2022 Nov;
110(1):84-91.
PMID: 36322464
Background: Significant barriers exist to surgeons being good parents and parents being good surgeons, and these barriers are heightened for women. Considering the gender balance now present in postgraduate medical...
20.
Commons R, Charles J, Cheney J, Lynar S, Malone M, Raby E
J Foot Ankle Res
. 2022 Jun;
15(1):47.
PMID: 35676695
Background: Diabetes-related foot infections cause substantial morbidity and mortality, both globally and in Australia. There is a need for up-to-date evidence-based guidelines to ensure optimal management of patients with diabetes-related...